ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL

Stock Information for Calyxt Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Calyxt Inc.

Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells
Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update
Cellectis to Present a Development Update for eti-cel at ASH 2025
Cellectis to Report Third Quarter Financial Results on November 7, 2025
Cellectis' R&D Day Highlights Lasme-cel's Potential to Address Significant Unmet Need for Patients with r/r B-ALL
Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers
Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress
Cellectis Reports Second Quarter 2025 Financial Results & Business Updates

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.